Browse by Poster Presenter

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

W
Wągrodzki, Michał

Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
(P 09) A NOMOGRAM MODEL TO PREDICT THE OVERALL SURVIVAL OF ADOLESCENT AND YOUNG ADULT PATIENTS WITH LOCALLY ADVANCED EWING SARCOMA.
Michał Wągrodzki
Favorite
(P 545) NEOADJUVANT PEMBROLIZUMAB AND EFTILAGIMOD ALPHA WITH CONCURRENT RADIOTHERAPY IN PATIENTS WITH SELECTED SOFT TISSUE SARCOMA SUBTYPES (EFTISARC-NEO)
Michał Wągrodzki
Favorite
Wachter, Franziska

Dana-Farber Cancer Institute
(P 384) SYSTEMATIC LITERATURE AND CLINICAL TRIAL REVIEW SHOWS TARGETABLE KINASE FUSIONS ARE COMMON IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SOFT TISSUE SARCOMAS BUT CLINICAL TRIAL OPPORTUNITIES REMAIN RARE
Franziska Wachter
Favorite
Wagner, Andrew

Dana-Farber Cancer Institute
(P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Andrew Wagner
Favorite
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Andrew Wagner
Favorite
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Andrew Wagner
Favorite
Wagner, Elizabeth

Nationwide Children's Hospital
(P 425) CHARACTERIZATION OF RHABDOMYOSARCOMA WITH PAX7::FOXO1 FUSIONS: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Elizabeth Wagner
Favorite
Wagner, Lars

Duke Children's Hospital
(P 537) TGFβ IMPRINTED, EX VIVO EXPANDED UNIVERSAL DONOR NATURAL KILLER CELLS WITH CHEMOTHERAPY FOR RELAPSED BONE AND SOFT TISSUE SARCOMA - NCT05634369, REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Lars Wagner
Favorite
(P 551) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT RHABDOMYOSARCOMA: A CLINICAL TRIAL IN PROGRESS FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Lars Wagner
Favorite
Wagner, Michael

Dana Farber Cancer Institute
(P 67) GENOMIC CHARACTERIZATION OF CHONDROSARCOMA: A RARE SARCOMA WITH CLINICAL RESPONSES TO IMMUNE CHECKPOINT INHIBITION
Michael Wagner
Favorite
Wagner, Michael

University of Washington/Fred Hutch/Seattle Cancer Care Alliance
(P 135) UNMET NEEDS IN LOCALLY ADVANCED (UNRESECTABLE) OR METASTATIC DEDIFFERENTIATED LIPOSARCOMA AND EXPECTATIONS FOR CLINICAL TRIALS: AN INTERNATIONAL DELPHI CONSENSUS STUDY
Michael Wagner
Favorite
Wagner, Michael

Dana Farber Cancer Institute
(P 177) ANGIOSARCOMA: AN INCREASING PROBLEM IN THE UNITED STATES
Michael Wagner
Favorite
Wagner, Michael

University of Washington/Fred Hutch/Seattle Cancer Care Alliance
(P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Michael Wagner
Favorite
(P 207) A MULTICENTER PHASE II STUDY OF CABOZANTINIB PLUS NIVOLUMAB FOR PATIENTS WITH ADVANCED ANGIOSARCOMA PREVIOUSLY TREATED WITH A TAXANE: ALLIANCE A091902
Michael Wagner
Favorite
Wagner, Michael J

Clinical Research Division, Fred Hutchinson Cancer Center, University of Washington
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Michael J Wagner
Favorite
Wagrodzki, Michal

Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
(P 21) YOUNG ADULTS WITH NONMETASTATIC OPERABLE OSTEOSARCOMA TREATED PERIOPERATIVELY WITH METHOTREXATE, DOXORUBICIN AND CISPLATIN SCHEDULE, SINGLE INSTITUTION REPORT
Michal Wagrodzki
Favorite
Wagrodzki, Michal

Maria Sklodowska-Curie National Research Institute of Pathology, Warsaw Poland
(P 162) LONG TERM SAFETY AND EFFICACY OF COMBINED DOXORUBICIN-IFOSFAMIDE CHEMOTHERAPY WITH PREOPERATIVE HYPOFRACTIONATED RADIOTHERAPY IN MARGINALLY RESECTABLE SOFT TISSUE SARCOMAS
Michal Wagrodzki
Favorite
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Michal Wagrodzki
Favorite
(P 310) PREOPERATIVE RADIOTHERAPY WITH HYPERTHERMIA IN RECURRENT AND RADIATION-INDUCED SARCOMAS: RESULTS OF A PHASE 2 CLINICAL TRIAL
Michal Wagrodzki
Favorite
Waissi, Waisse

CENTRE LEON BERARD AND CANCER RESEARCH CENTER OF LYON (INSERM U1052-CNRS5286)
(P 382) NTRK1/2/3 FUSIONS DETECTION USING RNA-SEQ IN MESENCHYMAL TUMORS REVEALS ULTRA-RARE AND HISTO-SPECIFIC TARGETABLE ALTERATIONS: EXPERIENCE OF AN EXTENSIVE ROUTINE RESEARCH PROGRAM.
Waisse Waissi
Favorite
(P 435) ONCOGENIC FUSION YWHAE::NUTM2 DISRUPT EP300/BCOR INTERACTION
Waisse Waissi
Favorite
Walker, Robert L.

University of miami
(P 280) A CELL-BASED COMPOUND SCREENING IDENTIFIES AGENTS THAT SYNERGIZE WITH EVEROLIMUS IN SARCOMA
Robert L. Walker
Favorite
Wallace, Asjah

Duke University
(P 375) IDENTIFICATION OF METASTATIC CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA: SINGLE CELL RNA SEQUENCING AND CIBERSORT ANALYSIS
Asjah Wallace
Favorite
(P 393) INVESTIGATING THE ROLE OF HDACS IN THE PROGRESSION OF METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Asjah Wallace
Favorite
Wallander, Karin

Karolinska Institutet
(P 230) SARCDBASE: A TOOL FOR DETECTION OF GENETIC ALTERATIONS IN SARCOMA
Karin Wallander
Favorite
(P 243) EVALUATION OF THE USE OF WGS IN ROUTINE DIAGNOSTICS FOR BONE AND SOFT TISSUE TUMORS
Karin Wallander
Favorite
Walling, Emily

University of Michigan, Department of Pediatric Hematology/Oncology
(P 07) IDENTIFYING CONCERNS OF ADOLESCENT AND YOUNG ADULT SARCOMA PATIENTS AND SURVIVORS FOLLOWING FERTIITY PRESERVATION
Emily Walling
Favorite
Walters, Ian

Intensity Therapeutics
(P 164) INTRATUMORAL INT230-6 (CISPLATIN, VINBLASTINE, SHAO) ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE SAFETY AND IMMUNE ACTIVATION IN ADULTS WITH REFRACTORY SARCOMAS (NCT 03058289)
Ian Walters
Favorite
Waltner, Olivia

Fred Hutchinson Cancer Center
(P 448) CAF-LIKE EWING SARCOMA CELLS DEPOSIT PRO-TUMORIGENIC EXTRACELLULAR MATRIX IN RESPONSE TO TGF-BETA SIGNALING
Olivia Waltner
Favorite
Wang, Baogui

Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer; Tianjin Key Laboratory of Digestive Cancer, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, P. R. China
(P 42) THE EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A SINGLE-INSTITUTION ANALYSIS
Baogui Wang
Favorite
Wang, Bingwu

Department of Spine Surgery, Weifang People's Hospital
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Bingwu Wang
Favorite
Wang, Chao-Chi

Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute
(P 43) UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN AS A POTENTIAL NEXT GENERATION MOLECULAR TARGET FOR TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
Chao-Chi Wang
Favorite
(P 254) A COLLECTION OF PATIENT-DERIVED XENOGRAFT MODELS OF GASTROINTESTINAL STROMAL TUMORS
Chao-Chi Wang
Favorite
(P 349) THE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN (UPARAP) IS AN ATTRACTIVE TARGET FOR THE DEVELOPMENT OF ANTIBODY DRUG CONJUGATES FOR TREATMENT OF MESENCHYMAL MALIGNANCIES
Chao-Chi Wang
Favorite
Wang, Dian

Rush University Medical Center
(P 307) IS RADIOTHERAPY NECESSARY FOR MANAGEMENT OF LOW GRADE MYXOID LIPOSARCOMA? A SYSTEMATIC REVIEW
Dian Wang
Favorite
Wang, Guocan

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
(P 256) EFFICACY AND TOXICITY OF VERTEPORFIN IN COMBINATION WITH PAZOPANIB TESTED IN A PATIENT-DERIVED SYNOVIAL SARCOMA XENOGRAFT
Guocan Wang
Favorite
Wang, Han

Peking University People's Hospital
(P 464) INDOCYANINE GREEN FLUORESCENCE IMAGING MAY DETECT TUMOUR RESIDUALS DURING SURGERY FOR BONE AND SOFT-TISSUE TUMOURS
Han Wang
Favorite
Wang, Jing

Department of Sport Surgery and Sport Medicine, Hunan Provincial People's Hospital
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Jing Wang
Favorite
Wang, Jiongyuan

Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
(P 339) QUALITY OF SURGERY AND OUTCOME FOR GIANT RETROPERITONEAL LIPOSARCOMA TREATED WITHIN SEMI-ABDOMINAL EN BLOC RESECTION USING VASCULAR PRIORITY CENTRAL APPROACH-A RETROSPECTIVE COHORT
Jiongyuan Wang
Favorite
(P 398) INTEGRATED MULTI-OMICS APPROACH REVEALED TUMOR-ASSOCIATED TERTIARY LYMPHOID STRUCTURE LANDSCAPE IN RETROPERITONEAL LIPOSARCOMA
Jiongyuan Wang
Favorite
Wang, Liang

Moffitt Cancer Center & Research Institute
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Liang Wang
Favorite
wang, ming

Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
ming wang
Favorite
Wang, Patrick Qi

University of Toronto
(P 443) SURGICAL RESECTION OF EXTREMITY EWING'S SARCOMA BASED ON POST-CHEMOTHERAPY TUMOUR VOLUME RESULTS IN SAFE MARGINS
Patrick Qi Wang
Favorite
(P 484) OBESITY INCREASES THE RISK OF MAJOR WOUND COMPLICATIONS FOLLOWING PELVIC RESECTION FOR BONE SARCOMA
Patrick Qi Wang
Favorite
Wang, Pin-Yi

Nationwide Children's Hospital
(P 94) DEVELOPING NOVEL OLIGONUCLEOTIDE THERAPIES TO MODULATE INSULIN RECEPTOR ALTERNATIVE SPLICING IN PEDIATRIC BONE SARCOMAS
Pin-Yi Wang
Favorite
(P 107) TRABECTEDIN AUGMENTS ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY EFFICACY IN PRECLINCAL BONE SARCOMA MODELS THROUGH ENHANCED IMMUNE-MEDIATED MECHANISMS
Pin-Yi Wang
Favorite
(P 125) MYELOMODULATORY TREATMENTS AUGMENT THE THERAPEUTIC BENEFIT OF ONCOLYTIC VIRUS IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS BY MODULATING THE TUMOR MICROENVIRONMENT
Pin-Yi Wang
Favorite
Wang, Shufeng

First Affiliated Hospital Xi'an Jiaotong University
(P 534) NEOADJUVANT CHEMOTHERAPY COMBINED WITH TARGETED TREATMENT IN HIGH-RISK RETROPERITONEAL SARCOMA – A PROSPECTIVE NON-RANDOMIZED CONTROLLED MULTI-CENTERED STUDY ALL ACROSS CHINA
Shufeng Wang
Favorite
Wangsiricharoen, Sintawat

The University of Texas MD Anderson Cancer Center
(P 198) PERSONALIZED MULTIDISCIPLINARY MANAGEMENT OF SARCOMA IN PATIENTS WITH LYNCH SYNDROME
Sintawat Wangsiricharoen
Favorite
wang, tao

Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
tao wang
Favorite
Wang, Wei-Lien

The University of Texas MD Anderson Cancer Center
(P 36) CLINICO-GENOMIC ANALYSIS OF KIT/PDGFRA/SDH WILD-TYPE GASTROINTESTINAL STROMAL TUMORS IDENTIFIES POTENTIAL DRIVER MUTATIONS
Wei-Lien Wang
Favorite
(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA
Wei-Lien Wang
Favorite
(P 83) CLINICO-GENOMIC PROFILING OF CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMAS REVEALS TP53 MUTATION TO BE ASSOCIATED WITH WORSE OUTCOMES
Wei-Lien Wang
Favorite
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Wei-Lien Wang
Favorite
(P 354) ROLE OF APPARENT DIFFUSION COEFFICIENT (ADC) MAP-BASED FIRST AND HIGH-ORDER RADIOMIC FEATURES IN DISCRIMINATING SACRAL CHORDOMAS AND CHONDROSARCOMAS WITH OVERLAPPING CONVENTIONAL IMAGING FEATURES
Wei-Lien Wang
Favorite
(P 360) TP53 ALTERATIONS IN SARCOMAS: AN ANALYSIS FROM THE AACR-GENIE DATABASE
Wei-Lien Wang
Favorite
Wang, Xiaona

Department of Gastric Surgery,Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer; Tianjin Key Laboratory of Digestive Cancer, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, P. R. China
(P 42) THE EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A SINGLE-INSTITUTION ANALYSIS
Xiaona Wang
Favorite
Wang, Xue

University of British Columbia
(P 267) NEW MOUSE MODEL OF SYNOVIAL SARCOMA BASED ON CONDITIONAL EXPRESSION IN MESENCHYMAL PROGENITORS
Xue Wang
Favorite
Wang, Yifei

UT MD Anderson Cancer Center
(P 89) GENERATION OF CHONDROCYTE-DERIVED MOUSE OSTEOSARCOMA MODELS - TRACKABLE SYSTEMS TO DELINEATE ONCOGENIC AND METASTATIC ENVENTS PRIOR TO TUMOROGENESIS
Yifei Wang
Favorite
(P 122) TARGETING CD70 USING CAR NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA
Yifei Wang
Favorite
(P 203) PRECLINICAL EVALUATION AMG 650, A SMALL MOLECULE INHIBITOR OF KIF18A, IN PEDIATRIC SOLID TUMORS BY THE PEDIATRIC PRECLINICAL IN VIVO TESTING (PIVOT) PROGRAM
Yifei Wang
Favorite
Wang, Zhenyu

School of Medicine, Anhui University of Science and Technology, Huainan, China
(P 339) QUALITY OF SURGERY AND OUTCOME FOR GIANT RETROPERITONEAL LIPOSARCOMA TREATED WITHIN SEMI-ABDOMINAL EN BLOC RESECTION USING VASCULAR PRIORITY CENTRAL APPROACH-A RETROSPECTIVE COHORT
Zhenyu Wang
Favorite
(P 398) INTEGRATED MULTI-OMICS APPROACH REVEALED TUMOR-ASSOCIATED TERTIARY LYMPHOID STRUCTURE LANDSCAPE IN RETROPERITONEAL LIPOSARCOMA
Zhenyu Wang
Favorite
Wani, Khalida

MD Anderson Cancer Center
(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)
Khalida Wani
Favorite
Wani, Khalida

The University of Texas MD Anderson Cancer Center
(P 198) PERSONALIZED MULTIDISCIPLINARY MANAGEMENT OF SARCOMA IN PATIENTS WITH LYNCH SYNDROME
Khalida Wani
Favorite
(P 405) PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE
Khalida Wani
Favorite
Wan, Jessica

Foghorn Therapeutics
(P 271) PHARMACODYNAMICS AND MECHANISTIC IMPACTS OF FHD-609, A BROMODOMAIN-CONTAINING PROTEIN 9 DEGRADER, IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR SMARCB1-LOSS TUMORS
Jessica Wan
Favorite
Wardelmann, Eva

Institute of Pathology,.University Hospital Muenster
(P 12) MULTIFOCAL AND DISSEMINATED SPORADIC DESMOID TUMOUR OF THE EXTREMITIES: A SPECIAL CHALLENGE
Eva Wardelmann
Favorite
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Eva Wardelmann
Favorite
Warren, Mikako

Children's Hospital Los Angeles
(P 430) UNIQUE HISTOLOGIC MORPHOLOGY OF EWING SARCOMA CELLS THAT HARBOR TP53 MUTATIONS
Mikako Warren
Favorite
Wartenberg, Markus

German Sarcoma Foundation (DSS), SPAGN
(P 136) SETTING THE INTERNATIONAL RESEARCH AGENDA FOR SARCOMA WITH PATIENTS AND CARERS: PRELIMINARY RESULTS OF PHASE II OF THE SARCOMA PATIENT ADVOCACY GLOBAL NETWORK (SPAGN) PRIORITY SETTING PARTNERSHIP
Markus Wartenberg
Favorite
(P 153) PRIORITY SETTING PARNTERSHIP RETROPERITONEAL SOFT TISSUE SARCOMAS
Markus Wartenberg
Favorite
Wasif, Nabil

Mayo Clinic Arizona
(P 141) TREATMENT VARIABILITY IN SURGICAL MANAGEMENT OF PULMONARY OLIGOMETASTATIC SOFT TISSUE SARCOMA
Nabil Wasif
Favorite
Waspe, Adam

Hospital for Sick Children
(P 108) EFFECT OF TUMOUR-TARGETED HYPERTHERMIA AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF EMBRYONAL RHABDOMYOSARCOMA
Adam Waspe
Favorite
Wasyl, Erikson

Moleculin Biotech, Inc.
(P 183) A PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (ANN) IN SUBJECTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS (STS) WITH PULMONARY METASTASES
Erikson Wasyl
Favorite
Watanabe, Itsuo

Tokyo Dental College Ichikawa General Hospital
(P 87) ANGIOSARCOMA OF THE ILIUM TREATED WITH HEMIPELVECTOMY AND HIP TRANSPOSITION FOLLOWED BY POSTOPERATIVE CHEMOTHERAPY WITH PAZOPANIB: A CASE REPORT
Itsuo Watanabe
Favorite
Waterfall, Joshua J

Institut Curie
(P 395) TARGETING CD44-MEDIATED IRON ENDOCYTOSIS IN DESMOID FIBROMATOSIS
Joshua J Waterfall
Favorite
Waters, Michael

Washington University in St Louis
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Michael Waters
Favorite
Watkins, James

Cambridge University Hospitals NHS Foundation Trust
(P 204) RADIATION-INDUCED ANGIOSARCOMA OF THE BREAST: RETROSPECTIVE ANALYSIS AT A REGIONAL TREATMENT CENTRE
James Watkins
Favorite
Watkins, Michael

University of Chicago
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Michael Watkins
Favorite
Watson, Caleb

Duke University
(P 72) CO-EXPRESSION OF LEUKOCYTE CYTOSOLIC PROTEIN 1 AND MATRIX METALLOPROTEINASES ARE INTEGRAL FOR METASTATIC PROGRESSION OF CHONDROSARCOMA
Caleb Watson
Favorite
Watson, Geoffrey

Mount Sinai Hospital / University of Toronto
(P 215) IMPACT OF FRONTLINE SYSTEMIC TREATMENT CHOICE ON CLINICAL OUTCOME IN ADVANCED LEIOMYOSARCOMA: A MULTI-CENTRE RETROSPECTIVE CANSARCC STUDY
Geoffrey Watson
Favorite
Watson, Sarah

Institut Curie
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Sarah Watson
Favorite
(P 395) TARGETING CD44-MEDIATED IRON ENDOCYTOSIS IN DESMOID FIBROMATOSIS
Sarah Watson
Favorite
Watson, Sasha

Sylvester Comprehensive Cancer Center / University of Miami Hospital and Clinics
(P 208) LOW INCIDENCE OF CANCER THERAPY-RELATED CARDIAC DYSFUNCTION IN ADULT SARCOMA PATIENTS RECEIVING DOXORUBICIN AND UPFRONT DEXRAZOXANE
Sasha Watson
Favorite
Watt, Tanya

University of Texas Southwestern Medical Center
(P 161) EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Tanya Watt
Favorite
Waymack, J

Moleculin Biotech, Inc
(P 183) A PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (ANN) IN SUBJECTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS (STS) WITH PULMONARY METASTASES
J Waymack
Favorite
Wayne, Jeff

Northwestern Memorial Hospital
(P 219) ELECTIVE DISCONTINUATION OF SORAFENIB TREATMENT IN DESMOID TUMORS: A RETROSPECTIVE ANALYSIS WITH IMPLICATIONS FOR CLINICAL PRACTICE
Jeff Wayne
Favorite
Weadick, Catherine S

CUH
(P 213) EXPERIENCE WITH THE USE OF TRABECTEDIN IN ADVANCED SOFT TISSUE SARCOMA IN IRELAND
Catherine S Weadick
Favorite
Webb, Angela

Peter MacCallum Cancer Centre
(P 516) OUCOMES OF AGGRESSIVE RESECTION OF RADIATION INDUCED ANGIOSARCOMA OF THE BREAST
Angela Webb
Favorite
Weber, Kristy

University of Pennsylvania
(P 529) THE MUSCULOSKELETAL TUMOR REGISTRY -- 2023 UPDATE AND OUTLOOK
Kristy Weber
Favorite
Weetall, Marla

PTC Therapeutics, Inc.
(P 182) UPDATED RESULTS FROM AN ONGOING PHASE 1B STUDY OF UNESBULIN (PTC596) PLUS DACARBAZINE FOR THE TREATMENT OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA
Marla Weetall
Favorite
(P 548) A PHASE 2/3 STUDY EVALUATING THE EFFICACY AND SAFETY OF UNESBULIN IN ADVANCED LEIOMYOSARCOMA (SUNRISELMS)
Marla Weetall
Favorite
Weiß, Christel

University Medical Center Mannheim
(P 488) POSTOPERATIVE DRAINAGE MANAGEMENT AND WOUND COMPLICATIONS FOLLOWING RESECTION OF LOWER LIMB SOFT TISSUE TUMORS
Christel Weiß
Favorite
Weigel, Brenda

Department of Pediatrics, University of Minnesota
(P 166) SARC038: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA
Brenda Weigel
Favorite
(P 167) FDG-PET-CT RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY PREDICTS LONG-TERM OUTCOME IN PATIENTS WITH SOFT TISSUE SARCOMA -- 15-YEAR FOLLOW-UP
Brenda Weigel
Favorite
(P 556) EVALUATION OF PALBOCICLIB (IBRANCE®) IN COMBINATION WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY EWING SARCOMA OR NEUROBLASTOMA
Brenda Weigel
Favorite
Weigl, Helene

University Medical Center Mannheim
(P 488) POSTOPERATIVE DRAINAGE MANAGEMENT AND WOUND COMPLICATIONS FOLLOWING RESECTION OF LOWER LIMB SOFT TISSUE TUMORS
Helene Weigl
Favorite
Weingertner, Noelle

University Hospital of Strasbourg
(P 389) OSTEOBLASTIC-GENE SIGNATURE TO PREDICT SURVIVAL IN PEDIATRIC OSTEOSARCOMA (OS) AND TO FOLLOW PATIENTS TOWARDS LIQUID BIOPSY: A COLLABORATIVE WORK IN OS2006 PROTOCOL.
Noelle Weingertner
Favorite
Wei, Ran

Peking University People's Hospital
(P 487) EN BLOC RESECTION FOR SPINAL TUMORS: A SINGLE CENTER EXPERIENCE OF 113 CONSECUTIVE CASES
Ran Wei
Favorite
Weiss, Aaron

Maine Children's Cancer Program
(P 13) OUTCOME OF PATIENTS WITH RELAPSED OR REFRACTORY NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMAS ENROLLED IN PHASE II COOPERATIVE GROUP CLINICAL TRIALS: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Aaron Weiss
Favorite
Weiss, Kurt

University of Pittsburgh
(P 244) A DEEP FEW-SHOT META-LEARNING STRATEGY FOR AUTONOMOUS CLASSIFICATION OF BONE METASTASIS IN RADIONUCLIDE BONE SCANS
Kurt Weiss
Favorite
(P 351) TARGETING ANDROGEN RECEPTOR IN OSTEOSARCOMA CELLS WITH VARYING METASTATIC POTENTIAL
Kurt Weiss
Favorite
(P 373) DEDIFFERENTIATED AND HIGH GRADE CHONDROSARCOMAS: HOW DOES ISOCITRATE DEHYDROGENASE STATUS APPRISE PROGNOSIS AND THERAPY?
Kurt Weiss
Favorite
(P 411) A SPATIAL TRANSCRIPTOMIC "GOOGLE MAP" OF HUMAN OSTEOSARCOMA REVEALS COMMON CELL CLUSTERS AT THE PRIMARY SITE AND PULMONARY METASTASES.
Kurt Weiss
Favorite
(P 466) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Kurt Weiss
Favorite
(P 536) PHASE 1 STUDY OF DISULFIRAM WITH COPPER GLUCONATE AND LIPOSOMAL DOXORUBICIN IN PATIENTS WITH TREATMENT REFRACTORY SARCOMAS
Kurt Weiss
Favorite
(P 544) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Kurt Weiss
Favorite
Weiss, Mia

Washington University School of Medicine
(P 180) HEALTH RELATED QUALITY OF LIFE OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMAS TREATED WITH CABOZANTINIB AND TEMOZOLOMIDE
Mia Weiss
Favorite
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Mia Weiss
Favorite
(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.
Mia Weiss
Favorite
Weiss, Sarah

Rutgers Cancer Institute of New Jersey
(P 183) A PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (ANN) IN SUBJECTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS (STS) WITH PULMONARY METASTASES
Sarah Weiss
Favorite
Weistuch, Corey

Department of Medical Physics, Memorial Sloan Kettering Cancer Center
(P 397) A MESENCHYMAL TISSUE LANDSCAPE TO STUDY OSTEOSARCOMA TUMOR HETEROGENEITY
Corey Weistuch
Favorite
Wei, Xing

Department of Medical Oncology, Peking University International Hospital
(P 534) NEOADJUVANT CHEMOTHERAPY COMBINED WITH TARGETED TREATMENT IN HIGH-RISK RETROPERITONEAL SARCOMA – A PROSPECTIVE NON-RANDOMIZED CONTROLLED MULTI-CENTERED STUDY ALL ACROSS CHINA
Xing Wei
Favorite
Weizhen, Liu

Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
(P 38) EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMORS: A MULTICENTER RETROSPECTIVE STUDY
Liu Weizhen
Favorite
Wenger, Doris

Mayo Clinic
(P 61) ADJACENT VENOUS TUMOR THROMBUS IN PRIMARY OSTEOSARCOMA OF THE PELVIS AND EXTREMITIES
Doris Wenger
Favorite
(P 62) PROSTHESIS-ASSOCIATED SARCOMA: A REVIEW OF 8 HIGH-GRADE LESIONS ARISING AROUND A TOTAL JOINT ARTHROPLASTY IMPLANT
Doris Wenger
Favorite
Wen, Haoxiang

The First Affiliated Hospital of Sun Yat-sen University
(P 45) THE LONG-TERM EFFECT OF IMATINIB WITH HEPATIC RESECTION OR OTHER LOCAL TREATMENT FOR GIST LIVER METASTASES
Haoxiang Wen
Favorite
Werier, Joel

The Ottawa Hospital
(P 98) TUMOR IMMUNE PROFILING AND IDENTIFICATION OF IMMUNOTHERAPEUTIC TARGETS IN DEDIFFERENTIATED LIPOSARCOMA
Joel Werier
Favorite
Werner, Jens

LMU University Hospital
(P 153) PRIORITY SETTING PARNTERSHIP RETROPERITONEAL SOFT TISSUE SARCOMAS
Jens Werner
Favorite
(P 348) RESECTION OF RECURRENT RETROPERITONEAL SOFT TISSUE SARCOMAS: ARE INTENSIVE MULTIMODAL TREATMENTS ASSOCIATED WITH INCREASED PERIOPERATIVE MORBIDITY?
Jens Werner
Favorite
Westlake, Babe

Renown Regional Medical Center
(P 93) INDETERMINATE CHEST LESIONS IN PATIENTS WITH BONE SARCOMA INCIDENTAL FINDING VERSUS METASTATIC DISEASE
Babe Westlake
Favorite
West, Nicholas

British Columbia Children's Hospital Research Institute
(P 512) PERIOPERATIVE BLOOD MANAGEMENT IN PEDIATRIC PATIENTS UNDERGOING PRIMARY OSTEOSARCOMA AND EWING SARCOMA RESECTION: A RETROSPECTIVE CASE NOTE REVIEW
Nicholas West
Favorite
Whalen, Giles

University of Massachusetts Memorial Medical Center
(P 164) INTRATUMORAL INT230-6 (CISPLATIN, VINBLASTINE, SHAO) ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE SAFETY AND IMMUNE ACTIVATION IN ADULTS WITH REFRACTORY SARCOMAS (NCT 03058289)
Giles Whalen
Favorite
Whiteway, Susan

Walter Reed National Military Medical Center
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Susan Whiteway
Favorite
Whiting, Karissa

Memorial Sloan Kettering Cancer Center
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Karissa Whiting
Favorite
Whittle, Sarah

Baylor College of Medicine
(P 165) MIDDLE EAR RHABDOMYOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Sarah Whittle
Favorite
Widemann, Brigitte

National Cancer Institute
(P 274) TYK2 AND MEK COMBINATION THERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND OTHER SOFT TISSUE SARCOMAS
Brigitte Widemann
Favorite
Widlund, Charlotte

Karolinska University Hospital
(P 278) CLINICAL MARKERS PREDICTIVE OF TRABECTEDIN RESPONSE IN SOFT TISSUE SARCOMA
Charlotte Widlund
Favorite
Wiegering, Armin

Department of General, Visceral, Transplantation, Vascular and Pediatric Surgery, University Hospital Würzburg, 97080 Würzburg, Germany
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Armin Wiegering
Favorite
Wiese, Michelle

Northwestern Medicine
(P 476) FAVORABLE RESULTS FOLLOWING TREATMENT OF UNICAMERAL BONE CYSTS WITH DOXYCYCLINE SCLEROGRAFT TECHNIQUE
Michelle Wiese
Favorite
(P 477) TREATMENT OF PROXIMAL FEMUR UNICAMERAL BONE CYSTS WITH DOXYCYCLINE SCLEROTHERAPY
Michelle Wiese
Favorite
Wijers-Koster, Pauline

LUMC
(P 368) DECODING THE IMMUNOGENOMIC DETERMINANTS OF RADIOTHERAPY RESPONSE IN SOFT TISSUE SARCOMAS
Pauline Wijers-Koster
Favorite
(P 369) MAGEA ANTIGENS AS IMMUNOTHERAPEUTIC TARGETS FOR ADVANCED OSTEOSARCOMA
Pauline Wijers-Koster
Favorite
Wijnen, Marc

Princess Maxima Center for Pediatric Oncology, The Netherlands
(P 251) EVALUATION OF POTENTIAL TARGETS FOR FLUORESCENCE-GUIDED SURGERY IN PEDIATRIC EWING SARCOMA: A PRECLINICAL PROOF-OF-CONCEPT STUDY
Marc Wijnen
Favorite
Wild, Tristan

University of Ottawa
(P 215) IMPACT OF FRONTLINE SYSTEMIC TREATMENT CHOICE ON CLINICAL OUTCOME IN ADVANCED LEIOMYOSARCOMA: A MULTI-CENTRE RETROSPECTIVE CANSARCC STUDY
Tristan Wild
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Tristan Wild
Favorite
Wilkinson, Michelle

The Royal Marsden Hospital
(P 40) LONG TERM OUTCOMES OF NEOADJUVANT IMATINIB AND SURGICAL RESECTION OF RECTAL GASTROINTESTINAL STROMAL TUMOURS
Michelle Wilkinson
Favorite
Wilkowski, Jodi

University of Michigan
(P 293) GENERATION OF A SPONTANEOUS IMMUNOCOMPETENT MOUSE MODEL OF LIPOSARCOMA
Jodi Wilkowski
Favorite
Wilky, Breelyn

University of Colorado Cancer Center
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Breelyn Wilky
Favorite
(P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY
Breelyn Wilky
Favorite
(P 237) SECONDARY REARRANGEMENT CREATING A PLEC-EML4-ALK DOUBLE FUSION AS A MECHANISM OF RESISTANCE TO CRIZOTINIB IN AN EML4-ALK-POSITIVE INFLAMMATORY MYOFIBROBLASTIC TUMOR
Breelyn Wilky
Favorite
(P 439) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 COMBINED WITH CHEMOTHERAPY IN EWING SARCOMA: PRELIMINARY DATA FROM A PHASE 1 STUDY
Breelyn Wilky
Favorite
(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.
Breelyn Wilky
Favorite
Williams, Dennis

Adaptimmune
(P 542) ENROLLMENT OF PEDIATRIC PARTICIPANTS WITH MAGE-A4-POSITIVE SOLID TUMORS IN A PHASE 1/2, OPEN-LABEL, BASKET TRIAL OF AFAMITRESGENE AUTOLEUCEL ("AFAMI-CEL")
Dennis Williams
Favorite
Williams, Kyle

Masonic Cancer Center University of Minnesota
(P 252) STUDY OF NUTRACEUTICAL INTERVENTION WITH HIGH PHENOLIC EXTRA VIRGIN OLIVE OIL AND CURCUMIN FOR NEUROFIBROMATOSIS TYPE 1
Kyle Williams
Favorite
Williams, NADINE

Loma Linda University
(P 525) ALL INTERNAL DISTRACTION OSTEOGENESIS AFTER TUMOR RESECTION
NADINE Williams
Favorite
(P 526) EVALUATION OF THE SURGICAL MANAGEMENT OF THE SKELETON IN PATIENTS WITH OLLIER'S DISEASE AND MAFUCCI SYNDROME
NADINE Williams
Favorite
Williams, Nadine

Loma Linda Medical Cancer Center
(P 527) SALVAGE OF AN OSTEOARRTICULAR ALLOGRAFT RADIUS RECONSTRUCTION SINGLE BONE TRANSPOSITION WITH WRIST ARTHRODESIS FOLLOWING OSTEOSARCOMA EXCISION
Nadine Williams
Favorite
Willis, Katelyn

Inhibrx, Inc
(P 29) COMBINATION TREATMENT WITH TEMOZOLOMIDE AND THE DEATH RECEPTOR-5 AGONIST INBRX-109 EFFECTIVELY TARGETS SUCCINATE DEHYDROGENASE -DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Katelyn Willis
Favorite
(P 439) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 COMBINED WITH CHEMOTHERAPY IN EWING SARCOMA: PRELIMINARY DATA FROM A PHASE 1 STUDY
Katelyn Willis
Favorite
Wilson, Isabella

Chris O'Brien Lifehouse
(P 194) REAL WORLD OUTCOMES OF PATIENTS TREATED WITH GEMCITABINE AND DOCETAXEL FOR ADVANCED SOFT TISSUE SARCOMA IN AN AUSTRALIAN SARCOMA CENTRE
Isabella Wilson
Favorite
Wilson, Roger

Founder - Sarcoma UK
(P 136) SETTING THE INTERNATIONAL RESEARCH AGENDA FOR SARCOMA WITH PATIENTS AND CARERS: PRELIMINARY RESULTS OF PHASE II OF THE SARCOMA PATIENT ADVOCACY GLOBAL NETWORK (SPAGN) PRIORITY SETTING PARTNERSHIP
Roger Wilson
Favorite
(P 186) PATIENT REPORTED OUTCOME ASSESSMENT AND REPORTING IN RANDOMIZED CLINICAL TRIALS OF SYSTEMIC THERAPY FOR ADVANCED SOFT TISSUE SARCOMAS: A SYSTEMATIC REVIEW.
Roger Wilson
Favorite
Wilson, William

CRUK & UCL Cancer Trials Centre
(P 70) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)
William Wilson
Favorite
Wilson, William

UCL Cancer Trials Centre
(P 472) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA). AN EARLY LOOK AT SURGICAL DATA
William Wilson
Favorite
Windsor, Rachael

University College London Hospital
(P 57) REAL-WORLD EXPERIENCE OF CABOZANTINIB IN PAEDIATRIC, TEENAGE AND YOUNG ADULT (TYA) AND ADULT METASTATIC BONE SARCOMA PATIENTS FROM THE LONDON SARCOMA SERVICE (LSS)
Rachael Windsor
Favorite
(P 422) CLINICAL UTILITY OF WHOLE GENOME SEQUENCING IN SARCOMA FOR THE IDENTIFICATION OF ACTIONABLE MUTATIONS: A RETROSPECTIVE COHORT ANALYSIS
Rachael Windsor
Favorite
Winer, Leah

Fox Chase Cancer Center
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Leah Winer
Favorite
Winters-Stone, Kerri

Oregon Health & Science University
(P 179) PILOT STUDY OF A REMOTELY DELIVERED RESISTANCE EXERCISE TRAINING PROGRAM IN SARCOMA SURVIVORS
Kerri Winters-Stone
Favorite
Wirta, Valtteri

SciLifeLab / Karolinska institutet
(P 243) EVALUATION OF THE USE OF WGS IN ROUTINE DIAGNOSTICS FOR BONE AND SOFT TISSUE TUMORS
Valtteri Wirta
Favorite
Witczak, Marcin

Early Phase Clinical Trials Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Marcin Witczak
Favorite
Woessmann, Wilhelm

University Medical Center Hamburg-Eppendorf
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Wilhelm Woessmann
Favorite
Wolden, Suzanne

Memorial Sloan Kettering Cancer Center
(P 165) MIDDLE EAR RHABDOMYOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Suzanne Wolden
Favorite
(P 320) A PROSPECTIVE MULTICENTER EXPERIENCE OF PROTON THERAPY FOR RHABDOMYOSARCOMA AND EWING SARCOMA: OUTCOMES FROM THE PROTON COLLABORATIVE GROUP REGISTRY
Suzanne Wolden
Favorite
(P 409) IMMUNOHISTOCHEMICAL STAINING FOR MYOGENIN, AP2 BETA AND HMGA2 PREDICT FOXO1 FUSION STATUS IN RHABDOMYOSARCOMA: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Suzanne Wolden
Favorite
(P 425) CHARACTERIZATION OF RHABDOMYOSARCOMA WITH PAX7::FOXO1 FUSIONS: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Suzanne Wolden
Favorite
(P 438) ALVEOLAR RHABDOMYOSARCOMA WITH "BURKITT-LIKE" MORPHOLOGY IS ASSOCIATED WITH HIGH AMPLIFICATION OF MYCL
Suzanne Wolden
Favorite
Wolinsky, Jean-Paul

Northwestern Medicine
(P 96) LEPTOMENINGEAL RECURRENCE OF EWING'S SARCOMA: A CASE SERIES
Jean-Paul Wolinsky
Favorite
Wong, Daniel

Sir Charles Gairdner Hospital (SCGH), Australia
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Daniel Wong
Favorite
Wong, Eric

The Chinese University of Hong Kong
(P 290) PRE-CLINICAL STUDY OF TUMOR TREATING FIELDS (TTFIELDS) ALONE OR IN CONJUNCTION WITH SYSTEMIC THERAPIES IN SELECTED BONE- AND SOFT-TISSUE SARCOMAS
Eric Wong
Favorite
Wong, Han

Cambridge University Hospitals NHS Foundation Trust
(P 204) RADIATION-INDUCED ANGIOSARCOMA OF THE BREAST: RETROSPECTIVE ANALYSIS AT A REGIONAL TREATMENT CENTRE
Han Wong
Favorite
(P 205) PRIMARY CARDIAC SARCOMA: A RETROSPECTIVE ANALYSIS OF PRESENTATION, MANAGEMENT AND OUTCOMES
Han Wong
Favorite
Wong, Jolene

Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore
(P 336) EVOLUTION AND PURSUIT OF EXCELLENCE IN SARCOMA MANAGEMENT IN AN ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Jolene Wong
Favorite
Wong, Justin

The University of Texas MD Anderson Cancer Center
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Justin Wong
Favorite
Wong, Philip

Princess Margaret Cancer Centre
(P 284) VALIDATING A NOVEL MICROFLUIDIC PLATFORM AS AN EX VIVO TUMOUR MODEL FOR SARCOMA DRUG DISCOVERY
Philip Wong
Favorite
(P 483) DID THE COVID-19 PANDEMIC NEGATIVELY AFFECT OUTCOMES FOR PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMAS?
Philip Wong
Favorite
Wong, Ru Xin

Division of Medical Oncology, National Cancer Centre Singapore
(P 82) PROGNOSTIC FACTORS AND OUTCOMES OF 275 PATIENTS WITH HEAD AND NECK BONE AND SOFT TISSUE SARCOMA: A SINGLE CENTRE COHORT STUDY
Ru Xin Wong
Favorite
Wong, Steven

Sarcoma Oncology Center
(P 117) INTERIM ANALYSIS OF PHASE 2 STUDY: A METRONOMIC REGIMEN USING GEMCITABINE, DOXORUBICIN, DOCETAXEL AND NIVOLUMAB FOR ADVANCED LEIOMYOSARCOMA (NCT04535713)
Steven Wong
Favorite
Wong, Suzanne

Hospital for Sick Children
(P 108) EFFECT OF TUMOUR-TARGETED HYPERTHERMIA AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF EMBRYONAL RHABDOMYOSARCOMA
Suzanne Wong
Favorite
Wooddell, Margaret

Daiichi Sankyo, Inc.
(P 199) PEXIDARTINIB RISK EVALUATION AND MITIGATION STRATEGY PROGRAM: 3-YEAR SAFETY DATA ASSESSMENT
Margaret Wooddell
Favorite
Wood, Georgina

University College London Hospital
(P 57) REAL-WORLD EXPERIENCE OF CABOZANTINIB IN PAEDIATRIC, TEENAGE AND YOUNG ADULT (TYA) AND ADULT METASTATIC BONE SARCOMA PATIENTS FROM THE LONDON SARCOMA SERVICE (LSS)
Georgina Wood
Favorite
(P 422) CLINICAL UTILITY OF WHOLE GENOME SEQUENCING IN SARCOMA FOR THE IDENTIFICATION OF ACTIONABLE MUTATIONS: A RETROSPECTIVE COHORT ANALYSIS
Georgina Wood
Favorite
Woods, Jacqueline

Clear Cell Sarcoma Foundation
(P 20) CLEAR CELL SARCOMA: PATIENT REPORTED REAL WORLD EVIDENCE
Jacqueline Woods
Favorite
Woods, Lennie

Clear Cell Sarcoma Foundation
(P 20) CLEAR CELL SARCOMA: PATIENT REPORTED REAL WORLD EVIDENCE
Lennie Woods
Favorite
Woods, Sara

Clear Cell Sarcoma Foundation
(P 20) CLEAR CELL SARCOMA: PATIENT REPORTED REAL WORLD EVIDENCE
Sara Woods
Favorite
Wooldridge, Adam

Medical College of Wisconsin
(P 181) REAL-WORLD EXPERIENCE WITH LIPOSOMAL DOXORUBICIN IN METASTATIC AND LOCALLY ADVANCED SARCOMA
Adam Wooldridge
Favorite
(P 473) GROIN PAINS: APPROACHES AND OUTCOMES FOR INGUINOFEMORAL SOFT TISSUE SARCOMAS
Adam Wooldridge
Favorite
Woo, Sang-Keun

Korea Institute of Radiological Medical Sciences
(P 78) THE CLINICAL OUTCOME OF EXTRASKELETAL MYXOID CHONDROSARCOMA
Sang-Keun Woo
Favorite
Wouters, Michel

Netherlands Cancer Institute/ Antoni van Leeuwenhoek
(P 32) IMPROVEMENT OF QUALITY AND TEXTBOOK OUTCOMES OF GASTRIC GASTROINTESTINAL STROMAL TUMOR (GIST) RESECTIONS IN THE PAST 13 YEARS; THE INFLUENCE OF MINIMAL INVASIVE SURGERY (MIS)
Michel Wouters
Favorite
Wozniak, Agnieszka

Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute
(P 43) UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN AS A POTENTIAL NEXT GENERATION MOLECULAR TARGET FOR TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
Agnieszka Wozniak
Favorite
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Agnieszka Wozniak
Favorite
(P 254) A COLLECTION OF PATIENT-DERIVED XENOGRAFT MODELS OF GASTROINTESTINAL STROMAL TUMORS
Agnieszka Wozniak
Favorite
(P 255) EPIDEMIOLOGY OF NOVEL ACTIONABLE TARGETS IN SYNOVIAL SARCOMA: A TISSUE MICRO-ARRAY STUDY
Agnieszka Wozniak
Favorite
(P 256) EFFICACY AND TOXICITY OF VERTEPORFIN IN COMBINATION WITH PAZOPANIB TESTED IN A PATIENT-DERIVED SYNOVIAL SARCOMA XENOGRAFT
Agnieszka Wozniak
Favorite
(P 349) THE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN (UPARAP) IS AN ATTRACTIVE TARGET FOR THE DEVELOPMENT OF ANTIBODY DRUG CONJUGATES FOR TREATMENT OF MESENCHYMAL MALIGNANCIES
Agnieszka Wozniak
Favorite
Wragg, Joseph

University of Birmingham
(P 282) AN EMBRYONIC ZEBRAFISH XENOGRAFT MODEL OF RHABDOMYOSARCOMA REVEALS GENOTYPE DEPENDENT TUMOUR VASCULARISATION DYNAMICS AND RESPONSE TO ANTI-ANGIOGENIC RECEPTOR TYROSINE KINASE INHIBITORS
Joseph Wragg
Favorite
Wrenn, Emma

Seattle Children's Research Institute
(P 447) TARGETING FOCAL ADHESION KINASE AUGMENTS THE THERAPEUTIC POTENTIAL OF BROMODOMAIN INHIBITORS IN EWING SARCOMA
Emma Wrenn
Favorite
(P 448) CAF-LIKE EWING SARCOMA CELLS DEPOSIT PRO-TUMORIGENIC EXTRACELLULAR MATRIX IN RESPONSE TO TGF-BETA SIGNALING
Emma Wrenn
Favorite
wu, Chia-Chin

The University of Texas MD Anderson Cancer Center
(P 405) PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE
Chia-Chin wu
Favorite
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Chia-Chin wu
Favorite
Wu, Jun

Department of Medical Oncology, The First People's Hospital of Changzhou
(P 44) RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY
Jun Wu
Favorite
Wunder, Jay

University of Toronto
(P 53) CURATIVE-INTENT SURGERY FOR A SOLITARY ISOLATED BONE METASTASIS FROM EXTREMITY SARCOMA: WHO UNDERWENT METASTASECTOMY AND WHAT WAS THE PROGNOSTIC OUTCOME?
Jay Wunder
Favorite
Wunder, Jay

Mount Sinai Hospital
(P 77) PATIENT OUTCOMES AFTER OPEN VERSUS CORE NEEDLE BIOPSY IN LOWER EXTREMITY SARCOMA
Jay Wunder
Favorite
Wunder, Jay

University of Toronto
(P 249) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Jay Wunder
Favorite
(P 352) DETERMINING THE CONTRIBUTIONS OF STAT1 TO THE UPS ANTI-TUMOR MICROENVIRONMENT
Jay Wunder
Favorite
(P 367) CHARACTERIZING HYPOXIA AND ASSOCIATED MOLECULAR FEATURES IN EXTREMITY SOFT TISSUE SARCOMA
Jay Wunder
Favorite
(P 443) SURGICAL RESECTION OF EXTREMITY EWING'S SARCOMA BASED ON POST-CHEMOTHERAPY TUMOUR VOLUME RESULTS IN SAFE MARGINS
Jay Wunder
Favorite
(P 483) DID THE COVID-19 PANDEMIC NEGATIVELY AFFECT OUTCOMES FOR PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMAS?
Jay Wunder
Favorite
(P 484) OBESITY INCREASES THE RISK OF MAJOR WOUND COMPLICATIONS FOLLOWING PELVIC RESECTION FOR BONE SARCOMA
Jay Wunder
Favorite
Wunker, Claire

Saint Louis University
(P 108) EFFECT OF TUMOUR-TARGETED HYPERTHERMIA AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF EMBRYONAL RHABDOMYOSARCOMA
Claire Wunker
Favorite
Wunker, Claire

Sinai Health System
(P 265) SELECTIVE TARGETING OF BET FAMILY EPIGENETIC REGULATORS IN ADVANCED AND METASTATIC ALVEOLAR RHABDOMYOSARCOMA
Claire Wunker
Favorite
Wu, Po-Kuei

Taipei Veterans General Hospital
(P 168) A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEXIDARTINIB IN ASIAN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Po-Kuei Wu
Favorite
Wu, Qing

Research Institute of the McGill University Health Center
(P 64) OSTEOSARCOMA. PATIENT-DERIVED XENOGRAFTS MODELS TO RECAPITULATE PATIENTS' CHEMORESISTANCE AND METASTATIC DISEASE
Qing Wu
Favorite
Wu, Xin

Chinese PLA General Hospital
(P 34) RIPRETINIB IN COMBINATION WITH OTHER TKIS IN CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A MULTI-CENTER RETROSPECTIVE ANALYSIS
Xin Wu
Favorite
Wu, Yu-Ching

National Taiwan University Hospital
(P 350) LIVER ANGIOSARCOMA IS ASSOCIATED WITH ARISTOLOCHIC ACID EXPOSURE AND HAS A DISTINCT TELOMERE MAINTENANCE MECHANISM
Yu-Ching Wu
Favorite
Wyns, Karo

Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute
(P 254) A COLLECTION OF PATIENT-DERIVED XENOGRAFT MODELS OF GASTROINTESTINAL STROMAL TUMORS
Karo Wyns
Favorite
(P 255) EPIDEMIOLOGY OF NOVEL ACTIONABLE TARGETS IN SYNOVIAL SARCOMA: A TISSUE MICRO-ARRAY STUDY
Karo Wyns
Favorite
Wytiaz, Victoria

University of Michigan, Department of Hematology/Oncology
(P 07) IDENTIFYING CONCERNS OF ADOLESCENT AND YOUNG ADULT SARCOMA PATIENTS AND SURVIVORS FOLLOWING FERTIITY PRESERVATION
Victoria Wytiaz
Favorite
(P 449) CIC-DUX4 sarcomas: A single-center review of clinical features and molecular aberrations identified through DNA sequencing
Victoria Wytiaz
Favorite